Gout

Although the DASH diet can lower gout risk in women regardless of genetics, nonadherence can result in a greater risk in those with a higher predisposition for elevated serum urate, according to a speaker at the EULAR 2021 Congress.

The FDA recently authorized sotrovimab to treat mild-to-moderate COVID-19 in individuals aged 12 years and older who are not hospitalized or require oxygen. The announcement was the top story in rheumatology last week.

Concomitant use of methotrexate and pegloticase resulted in “meaningful” improvements in joint assessments and patient-reported outcomes at 12 months in uncontrolled gout, according to data presented at the EULAR 2021 Virtual Congress.

Studies that feature work participation as an outcome in patients with inflammatory arthritis should identify key contextual factors — such as job type or social security system — upfront, according to new “points to consider” from EULAR.

Concomitant use of mycophenolate mofetil with pegloticase demonstrated clinically meaningful improvement in 86% of patients with uncontrolled gout, compared with pegloticase alone, according to data published in Arthritis & Rheumatology.

A study of patients on hemodialysis found pegloticase was successful in treating gout, while also demonstrating the potential to lower erythropoiesis-stimulating agent dose requirements following the therapy.

Although multiple observational studies in gout have reported significantly diminished mortality with allopurinol, these cannot be used as evidence due to time-related biases that exaggerate the drug’s benefits, according to data.

Weight gain from early adulthood to midlife, as well as consistent obesity throughout adulthood, were associated with an increased risk for gout, according to data published in Arthritis Research & Therapy.

Twitter use revealed “early signals” of drug rationing and other critical behavior changes in patients with rheumatic diseases as they navigated the early months of the COVID-19 pandemic, according to data published in Rheumatology.

Combining pegloticase with immunomodulation therapy greatly improves pegloticase response rates in patients with uncontrolled gout, according to a systematic review published in Seminars in Arthritis and Rheumatism.